文献速递眼底病与葡萄膜炎神经眼科

CNGA3突变全色盲视网膜基因治疗I期试验三年结果

Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial.
PubMed 文献 · Br J Ophthalmol · 2021-05-18

该开放标签非随机对照试验纳入9例CNGA3相关全色盲患者,分三个递增剂量组接受视网膜下AAV8.CNGA3基因治疗,随访3年。主要终点安全性得到确认,第1年观察到的功能获益持续至第2、3年,但多数疗效终点在治疗眼与未治疗对侧眼比较时未达统计学显著。

要点

  • 治疗3年内未发生与研究药物相关的不良或严重不良事件。
  • 第1年观察到的功能获益持续至第2年和第3年随访。
  • 多数疗效终点在治疗眼与未治疗对侧眼比较时未达统计学显著。

核心结论

  • 该基因治疗即使在高剂量组也表现出良好的安全性,但样本量小限制了疗效分析的统计效力。

主要发现

  • 第1年后未发生与研究药物相关的不良或严重不良事件。
  • 第1年观察到的治疗眼功能获益持续至第2年和第3年随访。
  • 部分次要终点在治疗眼达到统计学显著改善,但多数终点在治疗眼与未治疗对侧眼比较时未达统计学显著。

关键数值与推荐

  • 安全性作为主要终点得到确认,即使最高剂量组也未出现与研究药物相关的不良事件。

临床怎么用

  • 该试验结果可为未来临床试验设计最有希望的方案和终点提供参考。
  • 未来试验需确定治疗年轻患者是否因避免弱视这一潜在限制因素而获得更大功能获益。

局限性

  • 样本量小限制了疗效分析的统计效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To determine long-term safety and efficacy outcomes of a subretinal gene therapy for CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised controlled trial (NCT02610582). METHODS: Details of the study design have been previously described. Briefly, nine patients were treated in three escalating dose groups with subretinal AAV8.CNGA3 gene therapy between November 2015 and October 2016. After the first year, patients were seen on a yearly basis. Safety assessment constituted the primary endpoint. On a secondary level, multiple functional tests were carried out to determine efficacy of the therapy. RESULTS: No adverse or serious adverse events deemed related to the study drug occurred after year 1. Safety of the therapy, as the primary endpoint of this trial, can, therefore, be confirmed. The functional benefits that were noted in the treated eye at year 1 were persistent throughout the following visits at years 2 and 3. While functional improvement in the treated eye reached statistical significance for some secondary endpoints, for most endpoints, this was not the case when the treated eye was compared with the untreated fellow eye. CONCLUSION: The results demonstrate a very good safety profile of the therapy even at the highest dose administered. The small sample size limits the statistical power of efficacy analyses. However, trial results inform on the most promising design and endpoints for future clinical trials. Such trials have to determine whether treatment of younger patients results in greater functional gains by avoiding amblyopia as a potential limiting factor.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Reichel FF, Michalakis S, Wilhelm B, et al. Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial. Br J Ophthalmol. 2021. PMID: 34006508. doi:10.1136/bjophthalmol-2021-319067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。